Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. Outside of Eledon, Dr. Gros is the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products with over 500 employees. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.

Dr. Perrin was the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc. before joining Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) He has 20 years of drug development experience, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Over the past decade, Dr. Perrin has worked with the ALS Therapy Development Institute to develop the world’s largest ALS drug development program, bridging preclinical and clinical programs. Dr. Perrin earned a Ph.D. in Biochemistry from Boston University Medical Center, where he also started his career as Associate Professor of Medicine, and a Bachelor of Science from Boston College.

Ms. Escudero has served as Vice President, and Head of Clinical Operations since January 2024. Ms. Escudero has over 20 years of R&D experience in the pharmaceutical industry, where she has been involved in various stages of drug development, from early phase 1 trials to registrational phase 3 studies, which led to the successful registration of multiple small and large molecule pharmaceutical products. Prior to joining Eledon, Ms. Escudero served as VP of Clinical Development Operations at Leap Therapeutics, overseeing all operational facets of the clinical programs. Before Leap Therapeutics, she founded Caliber Clinical Consulting, LLC, providing independent consultation services to biopharmaceutical companies. Prior to Caliber Clinical Consulting, Ms. Escudero served as VP of Clinical Development Operations at Kiniksa Pharmaceuticals, where she managed multiple clinical programs at various stages of development. Ms. Escudero earned her B.S. in Behavior Neuroscience from Northeastern University.

Dr. Habibi has served as Vice President and Head of Safety & Pharmacovigilance of Eledon since February 2025, where she leads the company’s global safety and pharmacovigilance activities across its clinical programs. Prior to joining Eledon, Dr. Habibi held senior safety and pharmacovigilance leadership roles at CRISPR Therapeutics and Regenxbio, where she built high-performing global safety organizations and led global safety strategies for innovative therapeutics throughout clinical development and postmarketing stages. Over more than 20 years in global pharmacovigilance, she has directed safety strategy across a broad range of therapeutic areas, including oncology, gene therapy, gastroenterology, ophthalmology, rare diseases, and transplantation. Dr. Habibi earned her Doctor of Medicine from Shiraz University, School of Medicine and Healthcare Sciences, in Iran, and practiced family medicine before transitioning to a career in clinical research.

Mr. Herberger has served as Vice President, Technical Operations of Eledon since May 2022. Prior to joining Eledon, Mr. Herberger served as Senior Director, Manufacturing Science & Technology of Spark Therapeutics. Prior to joining Sparks Therapeutics, he served 21 years at Amgen where he held numerous leadership roles in drug delivery & formulation, device development, technology transfer and global operations. Mr. Herberger previously served on the University of Rhode Island College of Environmental & Life Sciences Dean’s Advisory Council and Bio Science Leaders Forum. Prior to joining Amgen, Mr. Herberger was a Research Scientist at Alkermes Inc., where he contributed to the development of novel drug delivery systems and authored several publications and patents in the field. Mr. Herberger began his career as a founding member of the Institute of Molecular Biology. He holds a bachelor’s degree from the University of Albany, State University of New York.

Dr. Hovland has served as Chief Regulatory Officer of Eledon since April 2021. In this role, he is responsible for Eledon’s Regulatory, Quality, and Safety functions. He has over 20 years of R&D experience in the pharmaceutical industry, and has contributed to the global development and registration of multiple small and large molecule pharmaceutical products. Dr. Hovland joined Eledon from Urovant Sciences, where he served as Senior Vice President, Global Regulatory Affairs and Quality. Before Urovant Sciences, Dr. Hovland held leadership roles within the Global Regulatory Affairs organization at Allergan, most recently serving as the Regulatory Affairs Therapeutic Area Head for Neurology, Urology, and Dermatology, with a previous role as Head of the Global Regulatory Operations function. Before Allergan, Dr. Hovland worked in Amgen’s Global Regulatory Affairs and Safety organization, serving as a global regulatory strategy leader on pharmaceutical development teams. Dr. Hovland earned his Ph.D. in Environmental Health Sciences from the School of Public Health at the University of California, Los Angeles, and his B.S. in Bioresource Sciences from the College of Natural Resources at the University of California, Berkeley.

Dr. Laurito-Trammell has served as Vice President, Clinical Development – Transplantation of Eledon since July 2023, where she leads the clinical development strategy and execution of the company’s transplantation programs. Prior to joining Eledon, Dr. Laurito-Trammell served as Clinical Development Medical Director at Novartis, where she contributed to the global clinical development of iscalimab, an investigational anti-CD40 monoclonal antibody for solid organ transplantation. Earlier in her career, she was a Clinical Research Scientist at Columbia University Irving Medical Center, where she led clinical research in liver transplantation, developed investigator-sponsored studies, and served as a member of the IRB. Over more than 15 years across academia and the biopharmaceutical industry, she has focused on clinical development, transplantation, immunology, and hepatology, dedicating the past decade to advancing innovative immunosuppressive therapies for solid organ transplantation and improving long-term outcomes for transplant recipients. Dr. Laurito-Trammell has authored numerous peer-reviewed publications and scientific presentations in the fields of transplantation and liver disease. She earned her MD from the University of Taubaté and completed her fellowship in Gastroenterology, postdoctoral training in Hepatology, and PhD in Clinical Hepatology at the Federal University of São Paulo (UNIFESP).

Dr. Li has served as Vice President, Biometrics of Eledon since January 2025. Prior to joining Eledon, Dr. Li held executive roles leading biometrics and data science functions, including biostatistics, statistical programming, data management, and clinical data analytics, in support of data-driven decision-making across drug development. Over more than 25 years, she has worked across global biopharmaceutical companies, biotech startups, and the FDA, supporting IND, NDA, and BLA submissions and global regulatory approvals across multiple therapeutic areas, including immunology and transplantation, oncology, CNS, women’s health, and metabolic disease. Dr. Li has contributed to the approvals of therapies including Zortress®, Femara®, Orgovyx®, and Myfembree®, as well as biosimilar antibody programs. She has authored more than 30 scientific publications in statistical methodology and medical research and has presented at FDA, EMA, PMDA, and DIA forums. Dr. Li holds a Ph.D. in Statistics from Oregon State University.

Mr. Little has served as Chief Financial Officer of Eledon since March 2021. Mr. Little has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., where he led finance, investor relations, information technology, and manufacturing. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) where he led the Company’s global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC’s Medical Aesthetics division and as a key member of the senior leadership team, helped build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.